TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05004116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repotrectinib
Description: TPX-0005 (Repotrectinib) will be taken orally twice daily in 28-day cycles without regard to food and will be administered orally before administration of irinotecan and temozolomide (exception: C1, TPX-0005 (Repotrectinib) will be administered once daily x 14 days, then twice daily D15-D28).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repotrectinib
Description: TPX-0005 (Repotrectinib) will be taken orally twice daily in 28-day cycles without regard to food and will be administered orally before administration of irinotecan and temozolomide (exception: C1, TPX-0005 (Repotrectinib) will be administered once daily x 14 days, then twice daily D15-D28).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repotrectinib
Description: TPX-0005 (Repotrectinib) will be taken orally twice daily in 28-day cycles without regard to food and will be administered orally before administration of irinotecan and temozolomide (exception: C1, TPX-0005 (Repotrectinib) will be administered once daily x 14 days, then twice daily D15-D28).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repotrectinib
Description: TPX-0005 (Repotrectinib) will be taken orally twice daily in 28-day cycles without regard to food and will be administered orally before administration of irinotecan and temozolomide (exception: C1, TPX-0005 (Repotrectinib) will be administered once daily x 14 days, then twice daily D15-D28).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repotrectinib
Description: TPX-0005 (Repotrectinib) will be taken orally twice daily in 28-day cycles without regard to food and will be administered orally before administration of irinotecan and temozolomide (exception: C1, TPX-0005 (Repotrectinib) will be administered once daily x 14 days, then twice daily D15-D28).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan and temozolomide
Description: Irinotecan and temozolomide will be given as per institutional standard.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan and temozolomide
Description: Irinotecan and temozolomide will be given as per institutional standard.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan and temozolomide
Description: Irinotecan and temozolomide will be given as per institutional standard.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan and temozolomide
Description: Irinotecan and temozolomide will be given as per institutional standard.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan and temozolomide
Description: Irinotecan and temozolomide will be given as per institutional standard.
Study: NCT04466553

Intervention type: DEVICE
Intervention: NICO BrainPath™ System
Description: Patients who are admitted under the neurology service in the Neurocritical Care and Medical ICU will be screened for participation in the trial by their treating physician. Once blood pressure has been stabilized and the best medical treatment has been determined, the patient will need to undergo a standard of care, repeat CT scan 6 hours after stabilization to show that there has been no increase in size of the ICH. Patients that meet eligibility criteria after this CT will be taken to the OR within 24-72 hours for a minimally invasive, navigation guided endoport based evacuation of the clot using the NICO BrainPath™ system.
Study: NCT06558669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh Sugarcane juice
Description: Fresh sugarcane juice in different doses will be given to liver patients for 90 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh Sugarcane juice
Description: Fresh sugarcane juice in different doses will be given to liver patients for 90 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fresh Sugarcane juice
Description: Fresh sugarcane juice in different doses will be given to liver patients for 90 days
Study: NCT06340633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ebselen
Description: Glutathione peroxidase mimetic

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo containing excipients
Study: NCT06524479

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SEEG recording and CCEP
Description: This study aims to utilize the clinical, imaging, and electrophysiological data of patients with drug-resistant epilepsy. By Performing CCEP detection at specific targets during both wakefulness and sleep and analyzing its electrophysiological characteristics, the study will compare the functional properties of white matter fibers during wakefulness and sleep.
Study: NCT06350955

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron isomaltoside
Description: single dose of 500 mg iron isomaltoside

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iron Carboxymaltose
Description: single dose of 500 mg ferric carboxymaltose
Study: NCT05644587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buprenorphine/naloxone
Description: Buprenorphine/naloxone will be used to begin each patient's treatment for opioid use disorder.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: buprenorphine/naloxone
Description: Buprenorphine/naloxone will be used to begin each patient's treatment for opioid use disorder.
Study: NCT06280846

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low-intensity laser acupuncture and Exercise therapy program
Description: The patients will receive low-intensity lasers and the treatment will be performed at 15 acupuncture points: unilateral GV3, GV4, and GV5, and bilateral BL 20, BL23, BL24, BL25, BL40 and GB30.~Exercise therapy program: The patients will perform an exercise therapy program in the form of:~- strengthening exercises for abdominal and back muscles, - lumbar stabilization exercises. - stretching exercises

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham laser acupuncture
Description: Sham laser acupuncture and exercise therapy program. The patients will receive a sham laser.acupuncture and an exercise therapy program in the form of: - strengthening exercises for abdominal and back muscles, - lumbar stabilization exercises. - stretching exercises
Study: NCT06789640

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vitamin C
Description: Vitamin C will be given before admission in the immediate preoperative preceding 7 days (the dose 30 -45 mg per day ) in oral drops preparations~Inflammatory markers including CRP , TLC ,PNI , GPS NLR will be checked on admission and on discharge and compared between cases and controls Hospital length stay will also be compared between the two groups

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be given before admission in the immediate preoperative preceding 7 days (the dose 30 -45 mg per day ) in oral drops preparations~Inflammatory markers including CRP , TLC ,PNI , GPS NLR will be checked on admission and on discharge and compared between cases and controls
Study: NCT04514757

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tVNS
Description: 20 Hz, 250ms at a current just below discomfort threshold for one hour twice a day, starting on post-day 0. Stimulation will continue until 5 days post-operatively or discharge.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham tVNS
Description: Current set a 0 mA, starting on post-op day 0. Stimulation will continue until 5 days post-operatively or discharge.
Study: NCT06469671

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The system based on real - time artificial intelligence - assisted for colonoscopy
Description: Russian medical decision support system based on artificial intelligence ArtInCol

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The system based on real - time artificial intelligence - assisted for colonoscopy
Description: Russian medical decision support system based on artificial intelligence ArtInCol
Study: NCT05913947

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lithium
Description: The starting dose (day one) of lithium citrate is 12 mmol (one tablet of lithium citrate contains 6 mmol lithium) given once a day before bedtime. On day three the dose is increased to 18 mmol. Dose adjustments are permitted after 7 days in a flexible manner to result in a 12-hour se-lithium between 0.6 and 0.8 mmol/l, aiming for the upper limit at the treating physician's discretion.
Study: NCT04866524

Intervention type: OTHER
Intervention: Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3
Description: Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy to use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.

Intervention type: OTHER
Intervention: Developmental score according to The Ages & Stages Questionnaires®, Third Edition - ASQ®-3
Description: Ages \& Stages Questionnaires®, Third Edition (ASQ®-3) is a developmental screening tool designed for use by early educators and health care professionals. It relies on parents as experts, is easy to use, family-friendly and creates the snapshot needed to catch delays and celebrate milestones.

Intervention type: OTHER
Intervention: Physical development and General Health
Description: Physical development and General health examination

Intervention type: OTHER
Intervention: Physical development and General Health
Description: Physical development and General health examination

Intervention type: OTHER
Intervention: Developmental Red flags
Description: Developmental Red flags Questionnaires
Study: NCT06785389

Intervention type: DIAGNOSTIC_TEST
Intervention: Fear of anesthesia, surgery and hospitals scale
Description: The day before surgery, patients will be interviewed using the scales of Fear of anesthesia, surgery and hospitals.

Intervention type: DIAGNOSTIC_TEST
Intervention: State-Trait Anxiety Inventory
Description: The day before surgery, patients will be interviewed using the State-Trait Anxiety Inventory

Intervention type: DIAGNOSTIC_TEST
Intervention: Nummerical Rating Scale for postoperative pain
Description: In the first postoperative day, patients will be monitored using the Nummerical Rating Scale, which will assess postoperative pain.
Study: NCT06788262

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cerebral MRI
Description: Cerebral MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cerebral MRI
Description: Cerebral MRI
Study: NCT06789094

Intervention type: OTHER
Intervention: Ain Shams University Cognitive Assessment (ASCA) tool
Description: The ASCA, developed at Ain Shams University, is a comprehensive tool designed for cognitive assessment in Egyptian population. It encompasses various tests to assess cognitive functions and cultural understanding. These include the Verbal Paired Associated Test, evaluating verbal learning, distractor interval, delayed recall, and word recognition. The Bender Gestalt assesses visual-motor skills and memory. Short-term and working memory are tested through Digit Forward and Digit Backward Span Length tasks. Set Shifting is measured using a modified Trail Making Test, adapted for illiterates. Additionally, tests for letter/lexical fluency, verbal fluency, language object naming, abstraction, and judgment offer further insights into cognitive abilities and cultural interpretation.

Intervention type: OTHER
Intervention: Ain Shams University Cognitive Assessment (ASCA) tool
Description: The ASCA, developed at Ain Shams University, is a comprehensive tool designed for cognitive assessment in Egyptian population. It encompasses various tests to assess cognitive functions and cultural understanding. These include the Verbal Paired Associated Test, evaluating verbal learning, distractor interval, delayed recall, and word recognition. The Bender Gestalt assesses visual-motor skills and memory. Short-term and working memory are tested through Digit Forward and Digit Backward Span Length tasks. Set Shifting is measured using a modified Trail Making Test, adapted for illiterates. Additionally, tests for letter/lexical fluency, verbal fluency, language object naming, abstraction, and judgment offer further insights into cognitive abilities and cultural interpretation.

Intervention type: OTHER
Intervention: Ain Shams University Cognitive Assessment (ASCA) tool
Description: The ASCA, developed at Ain Shams University, is a comprehensive tool designed for cognitive assessment in Egyptian population. It encompasses various tests to assess cognitive functions and cultural understanding. These include the Verbal Paired Associated Test, evaluating verbal learning, distractor interval, delayed recall, and word recognition. The Bender Gestalt assesses visual-motor skills and memory. Short-term and working memory are tested through Digit Forward and Digit Backward Span Length tasks. Set Shifting is measured using a modified Trail Making Test, adapted for illiterates. Additionally, tests for letter/lexical fluency, verbal fluency, language object naming, abstraction, and judgment offer further insights into cognitive abilities and cultural interpretation.
Study: NCT06789965

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SADI-S
Description: In the case of SADI-S, the complete dissection of the antrum and the first portion of the duodenum is performed up to the limit of the gastroduodenal artery. The right gastric artery is dissected, clipped, and sectioned at its root. A vertical gastrectomy is created using a 38F Foucher tube with staplers. Next, the duodenum is sectioned with a stapler, and the resection of the greater gastric curvature is completed. Then, from the left side of the patient, 250 cm is measured from the ileocecal valve, where the duodenoileal anastomosis will be performed. This anastomosis is carried out with the surgeon positioned again between the patient's legs. A manual end-to-side anastomosis with two layers of monofilament is performed. Finally, the vertical gastrectomy and the duodenoileal anastomosis are verified using intraoperative endoscopy or a methylene blue and air test. The gastrectomy specimen is removed through the left pararectal trocar incision. A drain will only be placed in cases of s

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: RY-GBP
Description: In the case of RY-GBP, first, the lesser gastric curvature is dissected between the cardia and the angular incisura, accessing the gastric transcavity. A horizontal gastric transection is performed using the first firing of a stapler. A gastric reservoir is created through successive firings with a 38F Foucher tube stapler. Next, 100 cm of the biliopancreatic limb is measured, where the manual or semi-mechanical gastrojejunostomy will be performed, with an end-to-side anastomosis using a stapler and manual closure of the loop. Then, 150 cm of the alimentary limb is measured, and a side-to-side jejunojejunostomy is created. A section is made between the two anastomoses. The mesenteric opening and the Petersen space are closed with a continuous non-absorbable suture. The anastomosis is verified using intraoperative endoscopy or a methylene blue and air test. A drain will only be placed in cases of special technical difficulty or intraoperative complications.
Study: NCT06788639

Intervention type: BIOLOGICAL
Intervention: Lisocabtagene maraleucel
Description: According to the United States Prescribing Information
Study: NCT06788236

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AVTR101
Description: three times daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: three times daily
Study: NCT06789575

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: the patients will receive the content of a syringe (10 ml of bupivacaine 0.25%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: the patients will receive the content of a syringe (10 ml of bupivacaine 0.25%)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenaline
Description: the patients will receive the content of a syringe 15 μg adrenaline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adrenaline
Description: the patients will receive the content of a syringe 15 μg adrenaline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine (drug)
Description: the patients will receive the content of a syringe 70 ml Lidocaine .

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine (drug)
Description: the patients will receive the content of a syringe 70 ml Lidocaine .
Study: NCT04062344

Intervention type: OTHER
Intervention: Swab
Description: Rectal swab before and after the drug provocation testing

Intervention type: OTHER
Intervention: Swab
Description: Rectal swab before and after the drug provocation testing
Study: NCT06789484

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Given daily from enrollement to 28 days of life

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given daily from enrollement to 28 days of life
Study: NCT06788743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIVA ( anesthesia with propofol and remifentanil)
Description: Participants assigned to the TIVA group will receive propofol combined with remifentanil for anesthesia maintenance during the surgery

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VA（anesthesia with sevoflurane and remifentanil）
Description: Participants assigned to the VA group will receive sevoflurane combined with remifentanil for anesthesia maintenance during the surgery.
Study: NCT05658510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXCL501
Description: Sublingual Film

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BXCL501
Description: Sublingual Film

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Sublingual Placebo Film

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Sublingual Placebo Film
Study: NCT06789250

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavior therapy
Description: The intervention within this study is based on cognitive behavioral therapy principles and adapted to target harmful alcohol use and mild to moderate alcohol use disorder co-occuring with psychological symptoms of depression, anxiety, stress and/or sleeping disorder. The 10 weeks of individually tailored treatment include psycho-educational texts as well as examples and exercises supported by a therapist.
Study: NCT06789523

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Friendship Bench
Description: The Friendship Bench model comprises 6 weekly, individual sessions with trained peer workers in addition to the usual care. Peer workers will help participants identify problems, outline potential solutions, and implement selected solutions.~The adaptation of Friendship Bench for Vietnamese methadone patients made revisions, such as removing the 'Belief in supernatural powers' section, replacing the Shona Symptom Questionnaire with DASS-21, and adding meth use. But this adaptation removed women-focused content on pregnancy and postpartum depression that we plan to include.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual psychiatric care
Description: Usual care includes monthly check-ups by peer workers, referral to hospital-based psychiatric services or other available mental health services if needed. This usual care might surpass standard psychiatric care in other provinces given that peer workers in Haiphong have been well trained on case management skills.
Study: NCT06789614

Intervention type: DRUG
Intervention: intravenous CYCLIZINE ,Metaclopromide
Description: US giuded measure of GRV in bariatrics surgery upon recieving drugs of study
Study: NCT06790095

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine (CsA)
Description: Intravenous (IV) injection, loading dose of 2.5 mg/kg (diluted in 0.9% NaCl to a final volume of 50 ml) given over 2 hours, immediately followed by a continuous IV infusion of of 5 mg/kg/day (diluted in 0.9% NaCl to a final volume of 250 ml) for 3 days (72-hour).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous (IV) injection of 0.9% NaCl with the same dosing strategy as CsA: loading dose given over 2 hours, immediately followed by a continuous IV infusion for 3 days (72-hour).
Study: NCT04866524

Intervention type: OTHER
Intervention: Developmental Red flags
Description: Developmental Red flags Questionnaires
Study: NCT06630325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study: NCT06052917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DECIdE
Description: DECIdE is a decision aid. Its a communication tool to help health providers as general practitioners or community pharmacists, to practice shared medical decision about optional prescription drug. DECIdE provide robust scientific data about benefit and risks associated to the drug under consideration. DECIdE was built based on the consensus of potentials users ( care providers and patients ), tested on users testing and finally validated by a expert consensus ( DELPHI method).
Study: NCT06789510

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous Platelet Rich Plasma
Description: 10 mL PRP intralesional injections will be administered. After the injections, participants will be instructed to perform penile stretching exercises daily until the next injection and to continue these exercises after the final injection until the 3-month follow-up.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: 10 mL saline solution intralesional injections will be administered. After the injections, participants will be instructed to perform penile stretching exercises daily until the next injection and to continue these exercises after the final injection until the 3-month follow-up.
Study: NCT06789146

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus posterior superior intercostal plane block
Description: Serratus posterior superior intercostal plane block will be performed on the patients using 30 ml of 0.25% bupivacaine under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracic Paravertebral Block
Description: Thoracic paravertebral block will be performed on the patients using 30 ml of 0.25% bupivacaine under ultrasound guidance.~Additionally, in the postoperative period a paracetamol dose of 1 g every 8 hours and a dexketoprofen dose of 50 mg twice daily were administered iv for multimodal analgesia.